Managing the side effects of sodium-glucose cotransporter-2 inhibitors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40750325.
- Also identified by DOI 10.3949/ccjm.92a.24071.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used because of their exceptional cardiovascular and renal benefits, their side effects and corresponding management strategies have not been well characterized to date. The latest evidence suggests that class effects of SGLT2 inhibitors include volume depletion, genital fungal infections, and euglycemic diabetic ketoacidosis, while medication-specific side effects include urinary tract infections with dapagliflozin and potential increased risk of amputations with canagliflozin. Management strategies include close monitoring, adjusting medication dosages, and temporarily holding SGLT2 inhibitors when appropriate.
Medical subject headings
- Sodium-Glucose Transporter 2 Inhibitors
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents